Gala Review
Best for: compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide
Gala (legal entity AI Coaching Inc., d/b/a Gala GLP-1) is a Delaware-incorporated telehealth platform offering compounded semaglutide and compounded tirzepatide on a yearly subscription, a lower-priced microdosing program, and brand-name Ozempic. The marketing site claims licensed providers in all 50 states with free shipping included. An oral Wegovy pill option is listed as 'coming soon.'
Medium confidence · Last verified 2026-05-07 via WebFetch live pull · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Gala is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Gala prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded GLP-1 | compounded | $179 |
| Compounded GLP-1/GIP | compounded | $179 |
| Microdosing GLP-1/GIP | compounded | $149 |
| Brand Ozempic | brand | $1299 |
✓ Pros
- •Compounded semaglutide and tirzepatide on a single platform at $179/month with all doses included on the yearly plan
- •Lower-priced microdosing tirzepatide tier at $149/month for patients who want a sub-therapeutic starting protocol
- •Brand-name Ozempic available alongside compounded options
- •Marketing site claims licensed providers in all 50 states with free shipping included
- •24/7 patient support and provider visit included; cancel anytime
- •LegitScript verification seal displayed on the marketing site
✗ Cons
- •$179/month rate is contingent on a yearly subscription; the standalone monthly price is not publicly disclosed on the landing pages
- •Brand-name Ozempic at $1,299/month is materially higher than peers offering brand Ozempic (e.g., Found at $1,100/month)
- •Pharmacy partners are not publicly named — site references a 'wide network of pharmacies across all 50 states' without attribution, which is a material YMYL transparency gap
- •Wegovy oral pill is advertised as 'coming soon' — not yet a live offering
- •Per-state availability list is not enumerated on the marketing site; the all-50-states claim is gated behind the signup intake
Ready to start with Gala?
Starting at $149/month. See current pricing and start your free consultation.
Sources & methodology
Our Gala review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Gala
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Gala?
Starting at $149/month. See current pricing and start your free consultation.